TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Thymosin alpha1 for Severe Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe sepsis according to ACCP/CCM criteria~* Patient or legally authorized representative able to provide informed consent~Exclusion Criteria:~* Subject is less than 18 years or more than 85 years of age~* If female, the subject is pregnant or nursing~* Subject is receiving immunosuppressive therapy such as cyclosporine, azothioprine,or cancer-related chemotherapy~* Patient not expected to survive 28 days because of uncorrectable medical condition, such as poorly controlled neoplasm or other end-stage disease~* History of bone marrow, lung, liver, pancreas, or small-bowel transplantation~* Acute pancreatitis with no established source of infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Thymosin alpha 1+Standard Therapy (Type: EXPERIMENTAL): Patients receive treatment based on SSC guideline with additional thymosin alpha1
- normal saline+standard therapy (Type: PLACEBO_COMPARATOR): Patients receive treatment based on SSC guideline with additional normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have advanced (stage III-IV) or recurrent histologically confirmed USPC with measurable disease.~* Patients must harbor a tumor HER2/neu+ based upon IHC staining score of 3+ or 2+ with confirmed gene amplification by FISH~Exclusion Criteria:~* Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancers, significant history of cardiac disease, uncontrolled hypertension, unstable medical issue, brain leptomeningeal, prior therapy with trastuzumab, uncontrolled seizure disorder, seropositive for HIV, active hepatitis, hemorrhagic diathesis or requiring supplemental oxygen.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carboplatin/Paclitaxel (Type: ACTIVE_COMPARATOR): Chemotherapy
- Trastuzumab (Type: EXPERIMENTAL): Monoclonal antibody

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients ages between 0 to and 65 years of age.~* Patient must have a genotypically HLA-identical sibling, a phenotypically matched first-degree relative or an unrelated matched donor.~* Acute lymphocytic leukemia (ALL) in CR1 with high risk features~* Acute myeloid leukemia (AML) in CR1 with high risk features defined as:~  i. Greater than 1 cycle of induction therapy required to achieve remission, ii. Preceding myelodysplastic syndrome (MDS) other than myelofibrosis, secondary AML iii. Presence of Flt3 mutations or internal tandem duplications, iv. FAB M6 or M7 classification or adverse cytogenetics for overall survival such as those associated with MDS, M6, M7 leukemia, or v. Complex karyotype \[\> 3 abnormalities\]~* Acute Leukemias in 2nd or greater remission~* Refractory or Relapsed AML~* AML transformed from MDS~* Myelodysplastic syndrome (MDS) beyond refractory anemia~* Chronic myeloid leukemia (CML)~* Chronic myelomonocytic leukemia~* Philadelphia-negative myeloproliferative disorder~* Relapsed chemotherapy-sensitive Hodgkin's or Non-Hodgkin's lymphoma~* Multiple Myeloma-Stage III~Exclusion Criteria:~* Prior autologous or allogeneic stem cell transplant.~* Performance status greater than 2~* Active infection.~* Inadequate cardiac function; arrythmias or symptomatic cardiac disease.~* Inadequate pulmonary function; FEV1, FVC, DLCO \<50% of predicted~* Inadequate Serum creatinine clearance \<60~* InadequatebHepatic function~* Positive serology for HIV-1, 2 or HTLV-1, 2.~* Pregnancy. Female patient must have negative pregnancy test

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Screening serum uric acid level ≥ 8 mg/dL;~* Body weight ≥ 50 kg and a body mass index (BMI) ≥ 18 and ≤ 40 kg/m2;~* Free of any clinically significant disease or medical condition, per the Investigator's judgment.~Exclusion Criteria:~* History or suspicion of kidney stones;~* Diagnosis of benign prostatic hypertrophy (BPH) or neurogenic bladder or evidence of BPH/neurogenic bladder such as thin urinary stream or difficulty in urination;~* An estimated creatinine clearance \< 60 mL/min calculated by the Cockcroft-Gault formula;~* QTcF interval (QT interval corrected for heart rate using Fridericia's formula) \> 450 msec at Screening;~* Receiving strong or moderate Cytochrome P450 (CYP) 3A inhibitors or p-glycoprotein inhibitors, or digoxin

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
- Cohort 2 (Type: EXPERIMENTAL): The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
- Cohort 3 (Type: EXPERIMENTAL): The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
- Cohort 4 (Type: EXPERIMENTAL): The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
- Cohort 5 (Type: EXPERIMENTAL): RDEA3170 2.5mg, RDEA3170 5mg, RDEA3170 10mg, RDEA3170 15mg
- Cohort 6 (Type: EXPERIMENTAL): The half of patients randomized to this cohort will be dosed in the order of Benzbromarone 50 mg, Febuxostat 10mg+RDEA3170 2.5 mg, then Febuxostat 20mg+RDEA3170 5 mg. The other half will be dosed in the order of Febuxostat 10mg+RDEA3170 2.5 mg, Febuxostat 20mg+RDEA3170 5 mg, then Benzbromarone 50mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with age between 18-75 years.~* Patients with chronic kidney disease stage 3 to 5, and concurrent chronic kidney disease mineral and bone disorder.~Exclusion Criteria:~* Renal artery stenosis, inherent renal malformation, solitary kidney, or malignancy in urinary system.~* New fracture in last 3 months.~* Active system immunity diseases.~* History of liver failure~* History of intestinal malabsorption or chronic diarrhea~* Treatment with phenobarbital, phenytoin, rifampicin, sucralfate, steroids, digoxin, or other medications that could affect vitamin D metabolism~* Primary hyperparathyroidism~* Treatment with cinacalcet or other calcimimetic within the past 6 months~* Anticipated dialysis within 6 months after randomization~* Have an unstable medical condition, defined as having been hospitalized within 30 days before screening, the expectation of recurrent hospital admissions or life expectancy of less than 6 months in the judgment of the investigator~* Subject is currently enrolled in, or fewer than 30 days have passed since subject has completed another investigational device or drug study(s); or subject is receiving another investigational agent(s).~* Current treatment with vitamin D 50,000 IU~* Using glucocorticoid or immunosuppressive agents.~* Acute renal dysfunction.~* The expected live time is less than 2 years.~* Pregnant or lactating woman.~* Suffered from acute myocardial infraction, acute congestive heart failure, or stroke in last 6 months.~* Patients whose concurrent illnesses, disability, or geographical residence would hamper attendance at required study visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D2 Treatment (Type: EXPERIMENTAL): Patients will be treated by vitamin D2. Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
- 1,25(OH)2 Vitamin D3 (Type: ACTIVE_COMPARATOR): Patients will be treated by 1,25(OH)2 Vitamin D3. Oral 1,25(OH)2 Vitamin D3(Rocaltrol) by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PF-06741086 Long-term Treatment in Severe Hemophilia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%)~* Subjects enrolled as Factor VIII or Factor IX inhibitor patients must have a positive inhibitor test result (above the upper limit of normal) at the local laboratory and must receive a bypass agent as primary treatment for bleeding episodes.~* Episodic (on-demand) treatment regimen prior to screening~* At least 6 acute bleeding episodes during the 6-month period prior to screening~Exclusion Criteria:~* Known coronary artery, thrombotic, or ischemic disease~* Concomitant treatment with activated prothrombin complex concentrate

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- PF-06741086 (Cohort 1) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 2) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 3) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 4) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 5) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 6) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Provex CV Supplement to Reduce Inflammation Cytokines and Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males (18 - 65) and postmenopausal females (up to age 65) with metabolic syndrome who have stage 1 hypertension.~* Since all subjects will have Stage 1 hypertension, they must also meet at least 2 of the following criteria of metabolic syndrome to qualify for the study; waist circumference of \>35 inches for women or \>40 inches in men, fasting plasma triglycerides of \>150 mg/dl, fasting glucose of \>100 mg/dl, HDL of \<40 in men. Pre-hypertension or greater (130 + mm Hg systolic/80+mm Hg diastolic) is defined by the 7th Report for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.~Exclusion Criteria:~* Subjects who are allergic to tea or grapes (on which the supplement is based).~* Participants who have blood pressure less than 130 mmHg / 80 mmHg,~* have a history of a prior cardiovascular event, diabetes, pregnancy, liver disease, renal insufficiency, any chronic disease that might interfere with study participation,~* BMI above 40 kg/m2,~* consumption of \>12 alcoholic drinks weekly,~* unwillingness to stop current supplement intake or use of calcium/ magnesium antacids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Participants will consume 330 mg of Provex CV supplement, by mouth, per day, for 4 weeks followed by 4 weeks of 330 mg of placebo (cornstarch)
- Arm 2 (Type: EXPERIMENTAL): Participants will consume 330 mg placebo (cornstarch), by mouth, per day for 4 weeks followed by 4 weeks of 330 mg of ProvexCV for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women (40 or older) with a diagnosis of primary OA of the knee~* Must be a current chronic user of NSAIDS or acetaminophen~* Must discontinue all analgesic therapy at screening~Exclusion Criteria:~* Uncontrolled hypertension or diabetes~* Hepatic or renal impairment~* Current or expected use of anticoagulant~* A history of alcohol or drug abuse~* Candidates for imminent joint replacement~* Diagnosis of gastric or duodenal ulceration and/or history of significant gastro-duodenal bleeding, within the last 6 months~* Current medical disease that could confound or interfere with the evaluation of efficacy~* Participation within 30 days prior to screening in another investigational study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo bid (Type: PLACEBO_COMPARATOR): At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
- Naproxcinod 375 mg bid (Type: EXPERIMENTAL): None
- Naproxen 500 mg bid (Type: ACTIVE_COMPARATOR): None
- Naproxcinod 750 mg bid (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of at least 1 Gastroesophageal Reflux Disease (GERD) symptom within 3 months of screening~* Positive esophagogastroduodenoscopy~* Signed informed consent~* Female patients (if menstruating) must be practicing birth control~Exclusion Criteria:~* Patients with history of esophagitis~* Patients who have milk protein allergy~* Patients who have taken Proton Pump Inhibitors or H2-blockers within 3 days~* Patients who have taken sucralate or any medication that affects gastrointestinal motility~* Patients with H. pylori~* Patients with lab values outside the normal age appropriate range~* Patients who have participated in another trial within 30 days before screening~* Patients with allergies to Proton Pump Inhibitors

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Rabeprazole 0.5 mg/kg (Type: EXPERIMENTAL): rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
- Rabeprazole 1.0 mg/kg (Type: EXPERIMENTAL): rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Main phase:~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Body mass index (BMI) greater than or equal to 30.0 kg/sqm or greater than or equal to 27.0 kg/sqm with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Extension phase:~* Informed consent for the extension phase obtained before any trial related activities for the extension phase~* On randomised treatment on the target dose at week 68, i.e. treated with 2.4 mg semaglutide once-weekly or semaglutide placebo~Exclusion Criteria:~Main phase:~* Glycated haemoglobin (HbA1C) greater than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening~* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records~Extension phase:~* Female who is pregnant or intends to become pregnant during the extension phase~* Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardise the subject's compliance with the extension of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide s.c. 2.4 mg once weekly (Type: EXPERIMENTAL): Participants will receive semaglutide for 68 weeks.
- Semaglutide placebo (Type: PLACEBO_COMPARATOR): Participants will receive semaglutide matching placebo for 68 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent~2. Aged 18-75 years~3. Histologically confirmed esophageal squamous cell carcinoma~4. Clinical stages T3-4N0M0 or TxN1M0 or TxNxM1a or TxNxM1b (Only for cervical lymph nodes or celiac lymph nodes metastasis) based on the 6th UICC-TNM classification~7. Eastern Cooperative Oncology Group(ECOG) performance status: 0-1 8. Life expectancy ≥3 months 9. Adequate organ functions Absolute neutrophil counts (ANC) ≥1.5×109⁄L; Hemoglobin (Hb) ≥9g⁄dl; Platelet (Plt) ≥100×109⁄L; Total bilirubin ≤1.5 upper limit of normal (ULN); Aspartate transaminase (AST) ≤2.5 ULN; Alanine aminotransferase (ALT) ≤2.5 ULN; Creatinine ≤1.5 ULN~Exclusion Criteria:~1. Esophageal perforation or hematemesis~2. Any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism and hypothyroidism (effective hormone replacement therapy excepted)) and immunosuppressive agents or systemic hormonal therapy indicated within 28 days (for adverse events of chemoradiotherapy excepted).~3. Previously received or receiving other PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1.~4. Allergic to macromolecular protein preparations, or to any of the ingredients in sintilimab for injection.~5. Uncontrolled heart diseases or clinical symptoms, such as: (1) New York Heart Association(NYHA) class II or higher heart failure; (2) unstable angina; (3) myocardial infarction within 1 year; (4)clinically significant arrhythmia requiring clinical intervention.~6. Congenital or acquired immunodeficiency (such as HIV infection); active hepatitis B (HBV-DNA≥104 copy number/ml) or hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the detection limit of the analytical method); active tuberculosis.~7. Active infection or unexplained fever \>38.5 °C within 2 weeks before randomization (fever due to tumor excepted, according to investigator).~8. Patients with fertility reluctant to take contraceptive measures during the trial, or female patients pregnant or breastfeeding.~9. According to the investigator, other factors that may cause termination of the study. ie, other serious diseases (including mental illness) require combined treatment, family or social factors, which may affect the safety or the collection of trial data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sintilimab plus chemotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete